Human Reproductive Technologies Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Market is Segmented by Reproductive Technology (Infertility Treatment and Contraceptives), Gender (Male and Female), End User (Fertility Clinics, Hospitals & Surgical Centers, and More), Product Mode (Drugs, Devices and Equipment), and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Human Reproductive Technologies Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Human Reproductive Technologies Market with other markets in Healthcare Industry

Human Reproductive Technologies Market Analysis by Mordor Intelligence

The human reproductive technology market stands at USD 32.64 billion in 2025 and is on course to reach USD 37.00 billion by 2030, advancing at a 2.54% CAGR. Demand is lifted by rising global infertility prevalence, later-in-life parenthood, and constant product innovation that now blends artificial intelligence, robotics, and genetic testing. Corporate fertility-benefit programs and expanding public reimbursement schemes further widen patient access, while private-equity consolidation accelerates clinical scale and standardization. At the same time, ethical debates, workforce shortages, and uneven insurance coverage temper expansion, creating a balanced yet durable growth profile for the human reproductive technology market. Competitive advantage increasingly hinges on technology adoption, data-driven care models, and the ability to serve both contraceptive and infertility segments under diversified service offerings.

Key Report Takeaways

  • By reproductive technology, contraceptives led with a 58.45% revenue share in 2024, while infertility treatments are projected to grow at a 3.12% CAGR to 2030. 
  • By gender, the female segment held 85.67% of human reproductive technology market share in 2024; male-focused solutions are forecast to expand at a 3.42% CAGR through 2030. 
  • By end user, fertility clinics accounted for 47.37% of human reproductive technology market size in 2024, whereas homecare and over-the-counter solutions will advance at a 3.81% CAGR to 2030. 
  • By product mode, drugs dominated with a 62.36% share of human reproductive technology market size in 2024; devices and equipment are set to grow at a 3.38% CAGR between 2025 and 2030. 
  • By geography, North America held 45.13% of human reproductive technology market share in 2024, with Asia-Pacific positioned for the fastest expansion at a 4.04% CAGR during the forecast horizon.

Segment Analysis

By Reproductive Technology: Contraceptive Pre-eminence Meets ART Momentum

Contraceptive solutions dominated revenue with a 58.45% stake in 2024, testifying to long-established demand across demographics. Oral pills remain the mainstay, yet long-acting reversible contraception gains share as next-generation intra-uterine systems introduce sustained-release mechanisms. In parallel, infertility treatments outpace overall human reproductive technology market growth, registering a 3.12% CAGR projected through 2030. Broadening public funding, AI-guided embryo analytics, and reduced procedural complexity propel treatment cycles higher, especially in Asia-Pacific clinics. Combination drug-and-device protocols lower stimulation doses and shorten cycle lengths, broadening patient appeal.

R&D investment targets gamete quality enhancement, non-invasive genetic testing, and robotic micromanipulation—areas anticipated to lift success-rate benchmarks beyond today’s 42% live-birth per cycle ceiling. As a result, integrated providers that offer both preventive and therapeutic services position themselves to capture rising cross-segment demand within the human reproductive technology market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Gender: Female Dominance Faces Rising Male Focus

The female segment commanded 85.67% of revenue in 2024, anchored by contraceptive prevalence and well-established fertility treatments. However, breakthrough male contraceptive pipelines promise to reshape share dynamics. A topical hormonal gel now in Phase III delivers 86% sperm suppression within 15 weeks, faster than historic injectables. Non-hormonal options such as selective retinoic acid receptor antagonists and hydrogel-based vas-occlusive implants advance through early trials, appealing to men seeking reversible methods without hormonal side effects.

Male infertility diagnostics also benefit from AI-assisted sperm-quality prediction, reducing laboratory workload while increasing predictive accuracy. These innovations explain the segment’s forecast-leading 3.42% CAGR, illustrating how the human reproductive technology industry is broadening gender-inclusive care portfolios.

By End User: Clinic Networks Strengthen as Homecare Scales

Fertility clinics retained 47.37% of 2024 revenue, underpinned by a wave of private-equity-backed roll-ups that streamline protocols and deepen technology investments. A 2024 peer-reviewed study found that newly consolidated chains improved live-birth rates by 13.6% and expanded cycle volume by 27% within two years. Homecare and OTC solutions, covering ovulation tests, at-home semen analysis, and self-injectable contraception, are set to climb at a 3.81% CAGR as consumers prioritize convenience and confidentiality.

Digital health platforms now integrate tele-consults, medication adherence tracking, and outcome analytics, linking clinics, pharmacies, and diagnostic labs into a cohesive patient journey. Hospitals and research institutes remain vital for complex interventions and technology validation, but the fastest-growing revenues increasingly flow from hybrid care pathways that bridge facility-based and home-based services within the human reproductive technology market.

Human Reproductive Technologies Market: Market Share by End User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Product Mode: Drug Supremacy Meets Accelerating Device Adoption

Drugs held 62.36% of human reproductive technology market size in 2024, covering ovarian stimulants, hormonal contraceptives, and adjunct therapies. Meanwhile, device revenue will rise at a 3.38% CAGR as AI-enabled imaging, robotic micromanipulators, and advanced culture systems gain traction. The U.S. FDA’s 2024 guidance for intravaginal culture devices set clear biocompatibility and performance standards, accelerating market entry for innovative systems.

Start-ups such as Gameto advance iPSC-derived ovarian support cells that mature oocytes outside the body, demonstrating how convergence of cell therapy and medical hardware can slash hormonal drug usage by 80%. Long-acting contraceptive implants incorporating nanotech carriers offer multi-year efficacy with minimal systemic exposure, highlighting how materials science upgrades will steadily narrow the gap between device and drug segments.

Geography Analysis

North America generated 45.13% of 2024 revenue, benefiting from mature healthcare financing, broad employer fertility benefits, and early adoption of AI-driven clinical protocols. The region also enacts supportive federal policy, exemplified by the 2025 executive order extending IVF benefits to military and civil-service families. Yet growth is partially constrained by a projected shortfall of 5,170 reproductive endocrinologists by 2030, which intensifies competition for clinical talent and incentivizes tele-medicine and robotic solutions to balance supply gaps.

Asia-Pacific represents the fastest-growing geography with a 4.04% CAGR expected through 2030. Policy levers play a central role: China’s exploration of national ART reimbursement could unlock millions of incremental treatment cycles per year. Japan’s updated surgical codes for IVF and ICSI similarly expand coverage, while Singapore and Malaysia subsidize up to 75% of treatment costs to combat declining birth rates. Fertility tourism into regional hubs further boosts procedure volumes and encourages high-tech clinic build-outs.

Europe maintains steady, mid-single-digit growth as universal health systems shield patients from high out-of-pocket spend. The region also hosts leading research networks such as ESHRE, which disseminate best-practice standards adopted worldwide. Regulatory debate over embryo-testing ethics and cross-border surrogacy can lengthen approval timelines, yet clinical sophistication and high disposable income sustain procedure uptake. Emerging economies in the Middle East, Africa, and South America still account for a modest slice of human reproductive technology market size, but investment in private clinics and technology transfer partnerships is catalyzing double-digit local growth rates from a low base.

Human Reproductive Technologies Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competition is moderate and trending toward concentration as private-equity funds roll up independent clinics to build national and regional networks. From 2017 to 2024, investors committed more than USD 625 million across 30-plus fertility platform deals, seeking scale advantages in marketing, lab automation, and payer contracting. Data from a 2024 Management Science study show that network clinics deliver 13.6% better live-birth outcomes post-integration, underscoring technical synergies.

Technology differentiation is equally decisive. AI-guided embryo-scoring software achieves 75–86% predictive accuracy, outperforming manual morphology and offering clinics a tangible success-rate edge. Robotic micromanipulation platforms reduce technician variability and enable remote operation, opening new tele-lab business models. Innovators such as Gameto, NEXT Life Sciences, and TMRW Life Sciences position themselves as ecosystem enablers through cell therapy, male contraception, and automated cryostorage, respectively.

Drug manufacturers remain essential partners, providing recombinant gonadotropins, progesterone support, and novel contraceptive formulations. Device specialists such as CooperSurgical and Hamilton Thorne supply consumables, imaging systems, and laser equipment that integrate with laboratory information software. Insurers and digital-health platforms like Progyny and Maven Clinic create a third axis of competition, using data analytics and bundled coverage to steer patients toward preferred provider networks, thereby influencing volume allocation within the human reproductive technology market.

Human Reproductive Technologies Industry Leaders

  1. CooperSurgical

  2. Teva Pharmaceutical Industries

  3. AbbVie Inc.

  4. Ferring B.V

  5. Merck KGaA

  6. *Disclaimer: Major Players sorted in no particular order
CooperSurgical, Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V, Merck KGaA
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: Conceive Fertility Foundation and the Wyatt Foundation introduced the 025 IVF grant program to offset patient treatment costs and support affordability research.
  • March 2025: Astorg launched Nexpring Health, a global MedTech company dedicated to assisted reproductive technology.
  • November 2024: SpOvum released SpOvum ARTGPT, an AI-powered platform designed to streamline patient interaction and decision support in fertility clinics.

Table of Contents for Human Reproductive Technologies Industry Report

1. Introduction

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence Of Infertility
    • 4.2.2 Continuous Technological Progress—Icsi, Pre-Implantation Genetic Testing
    • 4.2.3 Delayed Family Planning & Higher Maternal Age
    • 4.2.4 Growing Government Support & Reimbursement
    • 4.2.5 Employer-Funded Fertility-Benefit Programs
    • 4.2.6 Ai-Powered Embryo & Gamete Analytics
  • 4.3 Market Restraints
    • 4.3.1 Limited Insurance Coverage For Art
    • 4.3.2 Ethical & Religious Opposition
    • 4.3.3 Stringent Regulatory Pathways And Lengthy Approval Timelines
    • 4.3.4 Shortage Of Reproductive Endocrinologists
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Reproductive Technology
    • 5.1.1 Infertility Treatment
    • 5.1.1.1 Drugs
    • 5.1.1.1.1 Follitropin Alfa
    • 5.1.1.1.2 Follitropin Beta
    • 5.1.1.1.3 Menotropins
    • 5.1.1.1.4 Others
    • 5.1.1.2 Devices
    • 5.1.1.2.1 Sperm Separation Devices
    • 5.1.1.2.2 Sperm Analyzer Systems
    • 5.1.1.2.3 Ovum Aspiration Pumps
    • 5.1.1.2.4 Micromanipulator Systems
    • 5.1.1.2.5 Others
    • 5.1.2 Contraceptive
    • 5.1.2.1 Drugs
    • 5.1.2.1.1 Oral Contraceptives
    • 5.1.2.1.2 Topical Contraceptives
    • 5.1.2.1.3 Contraceptive Injectables
    • 5.1.2.2 Devices
    • 5.1.2.2.1 Condoms
    • 5.1.2.2.2 IUD
    • 5.1.2.2.3 Cervical Caps
    • 5.1.2.2.4 Diaphragms
  • 5.2 By Gender
    • 5.2.1 Male
    • 5.2.2 Female
  • 5.3 By End User
    • 5.3.1 Fertility Clinics
    • 5.3.2 Hospitals & Surgical Centers
    • 5.3.3 Homecare & OTC
    • 5.3.4 Research Institutes
  • 5.4 By Product Mode
    • 5.4.1 Drugs
    • 5.4.2 Devices & Equipment
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 CooperSurgical Inc.
    • 6.3.2 Teva Pharmaceutical Industries Ltd.
    • 6.3.3 AbbVie Inc.
    • 6.3.4 Ferring B.V.
    • 6.3.5 Merck KGaA
    • 6.3.6 Genea Limited
    • 6.3.7 IVFtech ApS
    • 6.3.8 Bayer AG
    • 6.3.9 Pfizer Inc.
    • 6.3.10 Organon & Co.
    • 6.3.11 Vitrolife AB
    • 6.3.12 Cook Medical LLC
    • 6.3.13 Thermo Fisher Scientific Inc.
    • 6.3.14 Boston IVF
    • 6.3.15 Virtus Health Ltd.
    • 6.3.16 Progyny Inc.
    • 6.3.17 Reckitt Benckiser Group plc
    • 6.3.18 Okamoto Industries Inc.
    • 6.3.19 Perrigo Company plc
    • 6.3.20 Care Fertility Group

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Human Reproductive Technologies Market Report Scope

As per the scope of the report, Human reproductive technologies involves all current and anticipated uses of technology in reproduction, including infertility treatments, contraceptives drugs and devices. These technologies deals with treating the infertility problems and conceiving.

By Reproductive Technology Infertility Treatment Drugs Follitropin Alfa
Follitropin Beta
Menotropins
Others
Devices Sperm Separation Devices
Sperm Analyzer Systems
Ovum Aspiration Pumps
Micromanipulator Systems
Others
Contraceptive Drugs Oral Contraceptives
Topical Contraceptives
Contraceptive Injectables
Devices Condoms
IUD
Cervical Caps
Diaphragms
By Gender Male
Female
By End User Fertility Clinics
Hospitals & Surgical Centers
Homecare & OTC
Research Institutes
By Product Mode Drugs
Devices & Equipment
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Reproductive Technology
Infertility Treatment Drugs Follitropin Alfa
Follitropin Beta
Menotropins
Others
Devices Sperm Separation Devices
Sperm Analyzer Systems
Ovum Aspiration Pumps
Micromanipulator Systems
Others
Contraceptive Drugs Oral Contraceptives
Topical Contraceptives
Contraceptive Injectables
Devices Condoms
IUD
Cervical Caps
Diaphragms
By Gender
Male
Female
By End User
Fertility Clinics
Hospitals & Surgical Centers
Homecare & OTC
Research Institutes
By Product Mode
Drugs
Devices & Equipment
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current Human Reproductive Technologies Market size?

The human reproductive technology market is valued at USD 32.64 billion in 2025.

Who are the key players in Human Reproductive Technologies Market?

CooperSurgical, Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V and Merck KGaA are the major companies operating in the Human Reproductive Technologies Market.

Which is the fastest growing region in Human Reproductive Technologies Market?

Asia-Pacific is forecast to post the quickest growth, at a 4.04% CAGR between 2025 and 2030.

Why are employer fertility-benefit programs important?

Corporate plans now cover 42% of U.S. employers, reducing out-of-pocket costs and expanding access to advanced fertility care.

Page last updated on: July 1, 2025

Human Reproductive Technologies Market Report Snapshots